Literature DB >> 22457354

Deletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell mass.

Michelle E Kimple1, Jennifer B Moss, Harpreet K Brar, Taylor C Rosa, Nathan A Truchan, Renee L Pasker, Christopher B Newgard, Patrick J Casey.   

Abstract

Insufficient plasma insulin levels caused by deficits in both pancreatic β-cell function and mass contribute to the pathogenesis of type 2 diabetes. This loss of insulin-producing capacity is termed β-cell decompensation. Our work is focused on defining the role(s) of guanine nucleotide-binding protein (G protein) signaling pathways in regulating β-cell decompensation. We have previously demonstrated that the α-subunit of the heterotrimeric G(z) protein, Gα(z), impairs insulin secretion by suppressing production of cAMP. Pancreatic islets from Gα(z)-null mice also exhibit constitutively increased cAMP production and augmented glucose-stimulated insulin secretion, suggesting that Gα(z) is a tonic inhibitor of adenylate cyclase, the enzyme responsible for the conversion of ATP to cAMP. In the present study, we show that mice genetically deficient for Gα(z) are protected from developing glucose intolerance when fed a high fat (45 kcal%) diet. In these mice, a robust increase in β-cell proliferation is correlated with significantly increased β-cell mass. Further, an endogenous Gα(z) signaling pathway, through circulating prostaglandin E activating the EP3 isoform of the E prostanoid receptor, appears to be up-regulated in insulin-resistant, glucose-intolerant mice. These results, along with those of our previous work, link signaling through Gα(z) to both major aspects of β-cell decompensation: insufficient β-cell function and mass.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457354      PMCID: PMC3370216          DOI: 10.1074/jbc.M112.359745

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  beta-Cell death during progression to diabetes.

Authors:  D Mathis; L Vence; C Benoist
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

Review 2.  Type 1 diabetes: recent developments.

Authors:  Devasenan Devendra; Edwin Liu; George S Eisenbarth
Journal:  BMJ       Date:  2004-03-27

Review 3.  The genetics of type 2 diabetes: what have we learned from GWAS?

Authors:  Liana K Billings; Jose C Florez
Journal:  Ann N Y Acad Sci       Date:  2010-11       Impact factor: 5.691

4.  Gz, a guanine nucleotide-binding protein with unique biochemical properties.

Authors:  P J Casey; H K Fong; M I Simon; A G Gilman
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

5.  Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes.

Authors:  Susanne M Clee; Samuel T Nadler; Alan D Attie
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

Review 6.  Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Authors:  Paul S Jellinger
Journal:  Postgrad Med       Date:  2011-01       Impact factor: 3.840

7.  Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity.

Authors:  P Keren; J George; A Shaish; H Levkovitz; Z Janakovic; A Afek; I Goldberg; J Kopolovic; G Keren; D Harats
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

8.  Galphaz negatively regulates insulin secretion and glucose clearance.

Authors:  Michelle E Kimple; Jamie W Joseph; Candice L Bailey; Patrick T Fueger; Ian A Hendry; Christopher B Newgard; Patrick J Casey
Journal:  J Biol Chem       Date:  2007-12-20       Impact factor: 5.157

Review 9.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

Authors:  S E Kahn
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122

10.  Deletion of guanine nucleotide binding protein alpha z subunit in mice induces a gene dose dependent tolerance to morphine.

Authors:  K J Leck; S E Bartlett; M T Smith; D Megirian; J Holgate; K L Powell; K I Matthaei; I A Hendry
Journal:  Neuropharmacology       Date:  2004-05       Impact factor: 5.250

View more
  22 in total

1.  A method for mouse pancreatic islet isolation and intracellular cAMP determination.

Authors:  Joshua C Neuman; Nathan A Truchan; Jamie W Joseph; Michelle E Kimple
Journal:  J Vis Exp       Date:  2014-06-25       Impact factor: 1.355

Review 2.  Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling.

Authors:  Bethany A Carboneau; Richard M Breyer; Maureen Gannon
Journal:  J Cell Commun Signal       Date:  2017-01-28       Impact factor: 5.782

Review 3.  Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.

Authors:  Rachel J Fenske; Michelle E Kimple
Journal:  Exp Biol Med (Maywood)       Date:  2018-03-04

Review 4.  The Beta Cell in Type 2 Diabetes.

Authors:  Ashley A Christensen; Maureen Gannon
Journal:  Curr Diab Rep       Date:  2019-08-09       Impact factor: 4.810

Review 5.  The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease.

Authors:  Michael D Schaid; Jaclyn A Wisinski; Michelle E Kimple
Journal:  AAPS J       Date:  2017-06-05       Impact factor: 4.009

6.  The gastrin-releasing peptide analog bombesin preserves exocrine and endocrine pancreas morphology and function during parenteral nutrition.

Authors:  Joseph F Pierre; Joshua C Neuman; Allison L Brill; Harpreet K Brar; Mary F Thompson; Mark T Cadena; Kelsey M Connors; Rebecca A Busch; Aaron F Heneghan; Candace M Cham; Elaina K Jones; Carly R Kibbe; Dawn B Davis; Guy E Groblewski; Kenneth A Kudsk; Michelle E Kimple
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-16       Impact factor: 4.052

7.  The Inhibitory G Protein α-Subunit, Gαz, Promotes Type 1 Diabetes-Like Pathophysiology in NOD Mice.

Authors:  Rachel J Fenske; Mark T Cadena; Quincy E Harenda; Haley N Wienkes; Kathryn Carbajal; Michael D Schaid; Erin Laundre; Allison L Brill; Nathan A Truchan; Harpreet Brar; Jaclyn Wisinski; Jinjin Cai; Timothy E Graham; Feyza Engin; Michelle E Kimple
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

8.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors:  Joshua C Neuman; Michelle E Kimple
Journal:  J Endocrinol Diabetes Obes       Date:  2013 Jul-Sep

Review 9.  Pancreatic β-cell proliferation in obesity.

Authors:  Amelia K Linnemann; Mieke Baan; Dawn Belt Davis
Journal:  Adv Nutr       Date:  2014-05-14       Impact factor: 8.701

10.  Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.

Authors:  Allison L Brill; Jaclyn A Wisinski; Mark T Cadena; Mary F Thompson; Rachel J Fenske; Harpreet K Brar; Michael D Schaid; Renee L Pasker; Michelle E Kimple
Journal:  Mol Endocrinol       Date:  2016-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.